

## LITERATURA

1. Suchopár J, Prokeš M, Suchopár O. Spotřeba antidepressiv v České republice ve srovnání s ostatními vyspělými zeměmi. *Remedia* 2016; 26(6): 560–566.
2. Raboch J, Červený R. Deprese, novelizace 2018. Centrum doporučených postupů pro praktické lékaře, dostupné z: [www.svl.cz](http://www.svl.cz)
3. Slanař O, Drazd'áková M, Babiárová K, Pechandová K, Buzková H, Perlík F, Zima T. Genotyping of CYP2D6 and CYP2C19. *Cas Lek Cesk* 2007; 146: 708–711.
4. Ústav lékařské biochemie a laboratorní diagnostiky VFN, dostupné z: <https://ulbld.lf1.cuni.cz/seznam-lab-vysetreni?vysetreni=1374>
5. SÚKL: Farmakoterapeutické informace 2015, 1: dostupné z: <http://www.sukl.cz/sukl/2015>
6. Prokeš M, Suchopár J. Serotoninový syndrom: co bychom o něm měli vědět. *Med. praxi* 2014; 11(5): 226–230.
7. Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. *Pain Physician* 2015; 18: 395–400.
8. Maniscalco I, Toffol E, Giupponi G, Conca A. The interaction of *Rhodiola rosea* and antidepressants. A case report. *Neuropsychiatr* 2015; 29: 36–38.
9. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: A retrospective survey. *Clin Infect Dis* 2006; 43: 180–187.
10. Attar-Herzberg D, Apel A, Gang N, et al. The serotonin syndrome: Initial misdiagnosis. *Isr Med Assoc J* 2009; 11: 367–370.
11. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. *Q J Med* 2003; 96: 635–642.
12. Prokeš M, Suchopár J. Proloužení intervalu QT způsobené léky. *Med. praxi* 2014; 11(1): 34–39.
13. Digby G, MacHaalany J, Malik P, et al. Multifactorial QT interval prolongation. *Cardiology Journal* 2010; 17: 184–188.
14. Woosley RL, Heise CW, Romero KA ([www.CredibleMeds.org](http://www.CredibleMeds.org)), QTdrugs List, [1. 3. 2018], AZCERT, Inc., 1822 Innovation Park Dr., Oro Valley, AZ 85755, USA, <https://www.crediblemeds.org/>
15. Helin-Salmivaara A, Huttunen T, Grönroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRI: a case-control study in the general population. *Eur J Clin Pharmacol* 2007; 63: 403–408.
16. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxin therapy. *Arch Gen Psychiatry* 2008; 65: 65(7): 795–803.
17. Gray SL, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern med* 2015; 175(3): 401–407.
18. Topinková E. Nežádoucí účinky antimuskarinik na centrální nervový systém. *Urol List* 2012; 10: 69–74.
19. Sheikh-Taha M, Dimassi H. Potentially inappropriate home medications among older patients with cardiovascular disease admitted to a cardiology service in USA. *BMC Cardiovascular Disorders* 2017; 17: 198.
20. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. *Expert Opin Drug Saf* 2017; 16(1): 77–87.
21. Wang D, Lai J, Lu S, Huang M, et al. Rapid-onset hyponatremia and delirium following duloxetine treatment for postherpetic neuralgia: Case report and literature review. *Medicine (Baltimore)*. 2018 Nov; 97(46): e13178.
22. Yoon HJ, Lee KY, Sun IO. Clinical severity of drug-induced hyponatremia: thiazides vs. psychotropics. *Clin Nephrol*. 2016 Jun; 85(6): 321–325.
23. Databáze lékových interakcí DrugAgency, 2019, Elektronická publikace. Dostupné z: <http://lekoveinterakce.cz>
24. Raboch J, Uhlíková P, Hellerová P, et al. Psychiatrie: Doporučené postupy psychiatrické péče IV. 2014. [cit. 2019–01–16]. Dostupné z: [https://psychiatrie.cz/images/stories/deni\\_v\\_oboru/doporucene-postupy-4-2014.pdf](https://psychiatrie.cz/images/stories/deni_v_oboru/doporucene-postupy-4-2014.pdf)
25. Karki SD, Masood GR. Combination risperidone and SSRI-induced serotonin syndrome. *Ann Pharmacother* 2003; 37(3): 388–391.
26. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. *J Clin Pharmacol* 2005; 25(6): 527–532.
27. Stout SM, Nielsen J, Welage LS, et al. The influence of metoprolol dosage release formulation on the pharmacokinetic drug interactions with paroxetine. *J Clin Pharmacol* 2011; 51: 389–396.
28. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the setereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. *Clin Pharmacol Ther* 2005; 77(4): 312–323.
29. Lantz MS, Buchalter EN, Giambanco V. Serotonin syndrome following the administration of tramadol with paroxetine. *Int J Geriatr Psychiatry* 1998; 13: 343–345.
30. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. *Psychopharmacology* 2001; 155(2): 219–220.
31. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. *Ther Drug Monit*. 2001 Aug; 23(4): 410–413.
32. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. *Drug Saf* 1991; 6(6): 460–462.